Endocrine pathologyHumansPancreatic NeoplasmsMaleFemaleMiddle Aged
Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
Louis de Mestier, Thorvardur R Halfdanarson, Leonidas Apostolidis, Anna Koumarianou, Jorge Hernando, Rachel Riechelmann, Emily K Bergsland, Sara Cingarlini, Shagufta Shaheen, Joakim Crona, Simon Kreutzfeldt, Osama Mosalem, Taymeyah Al-Toubah, Jérôme Cros, Jonathan R Strosberg
Published: 202510.1007/s12022-025-09887-8
Abstract
Alkylating agent-based chemotherapy is one of the main treatment options for patients with metastatic pancreatic neuroendocrine tumors (PanNETs).However, it favors the acquisition of a hypermutator phenotype, suggesting a potential benefit of immunot…
Preview only. Read the full abstract at the source